These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32333879)

  • 1. Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes.
    Ehrmann D; Kulzer B; Roos T; Haak T; Al-Khatib M; Hermanns N
    Lancet Diabetes Endocrinol; 2020 May; 8(5):436-446. PubMed ID: 32333879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.
    Goldenberg RM; Gilbert JD; Hramiak IM; Woo VC; Zinman B
    Diabetes Obes Metab; 2019 Oct; 21(10):2192-2202. PubMed ID: 31183975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
    Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
    Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent diabetic ketoacidosis and a brief history of brittle diabetes research: contemporary and past evidence in diabetic ketoacidosis research including mortality, mental health and prevention.
    Garrett CJ; Choudhary P; Amiel SA; Fonagy P; Ismail K
    Diabet Med; 2019 Nov; 36(11):1329-1335. PubMed ID: 31418474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol.
    Garg SK; Peters AL; Buse JB; Danne T
    Diabetes Technol Ther; 2018 Sep; 20(9):571-575. PubMed ID: 30129772
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
    Hampp C; Swain RS; Horgan C; Dee E; Qiang Y; Dutcher SK; Petrone A; Chen Tilney R; Maro JC; Panozzo CA
    Diabetes Care; 2020 Jan; 43(1):90-97. PubMed ID: 31601640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing Diabetic Ketoacidosis.
    Jefferies CA; Nakhla M; Derraik JG; Gunn AJ; Daneman D; Cutfield WS
    Pediatr Clin North Am; 2015 Aug; 62(4):857-71. PubMed ID: 26210621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic ketoacidosis: risk factors and management strategies.
    Umpierrez GE; Kitabchi AE
    Treat Endocrinol; 2003; 2(2):95-108. PubMed ID: 15871546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Socioeconomic factors associated with pediatric diabetic ketoacidosis admissions in Southern West Virginia.
    Lewis KR; Clark C; Velarde MC
    Clin Endocrinol (Oxf); 2014 Aug; 81(2):218-21. PubMed ID: 24117508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Incidence and related risk factors of diabetic ketoacidosis in Guangdong type 1 diabetics].
    Yan JH; Yang DZ; Deng HR; Li J; Weng JP
    Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(12):897-901. PubMed ID: 23863672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current concepts and controversies in prevention and treatment of diabetic ketoacidosis in children.
    Rewers A
    Curr Diab Rep; 2012 Oct; 12(5):524-32. PubMed ID: 22864672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
    Peters AL; Henry RR; Thakkar P; Tong C; Alba M
    Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors.
    Fleming N; Hamblin PS; Story D; Ekinci EI
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32302001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Frequency and clinical manifestation of diabetic ketoacidosis in children with newly diagnosed type 1 diabetes].
    Chumięcki M; Prokopowicz Z; Deja R; Jarosz-Chobot P
    Pediatr Endocrinol Diabetes Metab; 2013; 19(4):143-7. PubMed ID: 25612814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetes.
    Biester T; Kordonouri O; Danne T
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():53-61. PubMed ID: 31081591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrolithiasis: A complication of pediatric diabetic ketoacidosis.
    Agrawal S; Kremsdorf R; Uysal S; Fredette ME; Topor LS
    Pediatr Diabetes; 2018 Mar; 19(2):329-332. PubMed ID: 28737266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management.
    Kum-Nji JS; Gosmanov AR; Steinberg H; Dagogo-Jack S
    J Diabetes Complications; 2017 Mar; 31(3):611-614. PubMed ID: 27913012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Modality-Dependent Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes: Danish Adult Diabetes Database Study.
    Hoshina S; Andersen GS; Jørgensen ME; Ridderstråle M; Vistisen D; Andersen HU
    Diabetes Technol Ther; 2018 Mar; 20(3):229-234. PubMed ID: 29437465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA protocol.
    Rendell MS
    Diabetes Obes Metab; 2019 Oct; 21(10):2189-2191. PubMed ID: 31334593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.